Attached files
file | filename |
---|---|
8-K - FORM 8-K - BIOCLINICA INC | w77897e8vk.htm |
EX-4.1 - EX-4.1 - BIOCLINICA INC | w77897exv4w1.htm |
EX-2.1 - EX-2.1 - BIOCLINICA INC | w77897exv2w1.htm |
Exhibit 99.1
Company Contact Jim Dorsey | ||
BioClinica | ||
267-757-3040 | ||
Trade Media Beth Nestlerode | ||
Diccicco Battista Communications | ||
484-342-3600 | ||
Investor Contact Linda Decker | ||
Financial Media Bill Gordon | ||
Porter, LeVay & Rose, Inc. | ||
212-564-4700 |
FOR IMMEDIATE RELEASE
BIOCLINICA ACQUIRES TRANSENDA INTERNATIONAL, LLC
Adds Clinical Trial Management Software With Microsoft Office Interoperability
NEWTOWN, PA, March 26, 2010 BioClinica, Inc., (NASDAQ: BIOC), a global provider of clinical
trial management services, today announced its acquisition of substantially all of the assets of
privately held TranSenda International, LLC (TranSenda). Headquartered in Bellevue, WA,
TranSenda is a provider of clinical trial management software (CTMS) solutions and is a Microsoft
Gold Certified Partner.
TranSendas innovative suite of web-based, Office-Smart CTMS solutions and patent-pending
integration technologies create efficiencies for trial operations through interoperability with
Microsoft Office tools. With this acquisition, BioClinica enhances its ability to serve customers
throughout the clinical research process with technologies that include improved efficiencies by
reducing study durations and costs through integrated operational management.
TranSenda brings a line of Office-Smart clinical trial management solutions to BioClinica that
will become a part of our Microsoft Office-enabled delivery vision, said Mark Weinstein, CEO of
BioClinica. With the incorporation of TranSendas technology, our customers will benefit from the
compatibility and ease-of-use efficiencies that exist across the broader eClinical domain. This
acquisition is an important step forward as we continue to advance our integrated eClinical
solutions model and execute our strategy of bringing best-in-class technology and resources to our
customers.
Mr. Weinstein continued The acquisition of TranSenda not only enhances our portfolio of clinical
trial technology, it also provides us intellectual property with thought leaders and domain
experts in trial planning and management. We welcome Bob Webber and his team to BioClinica.
We are excited to join BioClinica as it will provide us the ability to expand our market reach
and delivery to the global marketplace and fulfill the demand for our technologies, said Robert
Webber, President of TranSenda International. We expect BioClinicas expertise, scope of quality
customer relationships and their overall global presence will be catalysts to the growth of our
technologies and market reach.
Information workers in the life sciences industry are often challenged with working across many
different systems throughout the clinical trial process, said Michael Naimoli, director of life
sciences industry solutions, Microsoft Corp. TranSenda has helped pharmaceutical companies
address these problems, providing solutions that allow professionals to work within the familiar
Microsoft Office environment. Were pleased that BioClinica customers will also benefit from these
tools and continue to simplify the workflow and clinical trials information management process.
-more-
Under the terms of the agreement, BioClinica is purchasing substantially all of the assets of
TranSenda for 577,960 shares of BioClinica unregistered common stock at closing. For 2010,
BioClinica expects TranSenda to contribute approximately $1.0 million in service revenue and an
operating loss of $500,000. Additional financial details will be provided when BioClinica
releases its first quarter 2010 results as well as full year 2010 guidance, which will include
TranSendas contribution. Additional terms of the agreement will be disclosed on a Form 8-K to be
filed the same day as this press release.
About BioClinica
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial
management services. BioClinica supports pharmaceutical and medical device innovation with imaging
core lab, internet image transport, electronic data capture, interactive voice and web response,
and clinical supply chain design and optimization solutions. BioClinica services maximize
efficiency and manageability throughout all phases of the clinical trial process. With more than
20 years of experience and over 2,000 successful trials to date, BioClinica has supported the
clinical development of many new medicines from early phase trials through final approval.
BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two
continents, and supports worldwide eClinical and data management services from offices in the
United States, Europe and Asia. For more information, please visit www.bioclinica.com.
Certain matters discussed in this press release are forward-looking statements intended to
qualify for the safe harbors from liability established by the Private Securities Litigation
Reform Act of 1995. In particular, the Companys statements regarding trends in the marketplace
and potential future results are examples of such forward-looking statements. The forward-looking
statements include risks and uncertainties, including, but not limited to, the consummation and
the successful integration of current and proposed acquisitions, the timing of projects due to the
variability in size, scope and duration of projects, estimates and guidance made by management
with respect to the Companys financial results, backlog, critical accounting policies, regulatory
delays, clinical study results which lead to reductions or cancellations of projects, and other
factors, including general economic conditions and regulatory developments, not within the
Companys control. The factors discussed herein and expressed from time to time in the Companys
filings with the Securities and Exchange Commission could cause actual results and developments to
be materially different from those expressed in or implied by such statements. The
forward-looking statements are made only as of the date of this press release and the Company
undertakes no obligation to publicly update such forward-looking statements to reflect subsequent
events or circumstance. You should review the Companys filings, especially risk factors contained
in the Form 10-K and the recent Form 10-Q.
######
-2-